

FOR IMMEDIATE RELEASE

Corindus Named to Fast Company’s “Most Innovative” List for 2021 Amid Global Expansion *Award recognition coincides with new global installations of CorPath® GRX and U.S. launch of technIQ™*

WALTHAM, Mass., March 9, 2021 — Corindus, A Siemens Healthineers Company and one of the leading developers of precision vascular robotics, announced today it has been named to *Fast Company*’s prestigious annual list of the World’s Most Innovative Companies for 2021, earning the No. 5 spot in the robotics category. The award recognizes Corindus and its robotic platform with developmental remote technology for its role in completing the first transcontinental cardiovascular test procedures in the U.S., which demonstrated telerobotic medicine’s potential to significantly expand patient access to care. Additionally, the company announced:

- It has expanded its global customer base within the last six months with signed agreements from Germany, Spain, South Africa, Australia, and Poland.
- A leading hospital in Dortmund, Germany became the first facility in the world to complete in-human interventions with the new technIQ Series movements and Siemens Healthineers’ ARTIS icono angiography imaging system, providing their clinicians the advantage of more precise medicine with automation and advanced imaging technologies.
- The University of Washington Medical Center performed the first-in-human robotic-assisted percutaneous coronary intervention (PCI) cases in the U.S. using new automated robotic movements from the technIQ Series, which the U.S. Food and Drug Administration (FDA) cleared in December 2020.

William Lombardi, MD, FACC, FSCAI, director for complex coronary artery disease therapies at the University of Washington Heart Institute, has developed novel maneuvers to treat chronic total occlusion (CTO) and complex PCI cases. The new technIQ movements replicate some of the manual techniques that he employs in those cases and make complex procedures more repeatable with consistent device movements through the vasculature.

“We are proud to be on the cutting edge of cardiovascular technology and we are honored to play a role in introducing the new technIQ automation to our department and our patients,” said Dr. Lombardi. “Enhancing physician capability with robotic-assisted technology allows us to handle the most challenging cases while continuously achieving positive outcomes for our patients.”

Each year, *Fast Company* honors the businesses making the most profound impact on both industry and culture, showcasing a variety of ways to thrive in today’s fast-changing world. This year’s winners include Moderna, Pfizer-BioNTech, and Microsoft, and previous honorees have included companies such as Tesla and Merck.

“Corindus has made significant progress toward our goal of expanding access to care through remote robotic interventions, and we are excited to validate those efforts with the recognition from *Fast Company*,” said Wayne Markowitz, Executive Vice President and Head of Corindus. “By combining our robotic platform with remote capability, data-driven automation and advanced imaging technology, we aim to recalibrate the standard of care with the goal of expanding the reach of high-level treatment to all patients regardless of their location. We look forward to building more new partnerships around the world and contributing to better health outcomes globally.”

To learn more about Corindus and CorPath GRX, please visit www.corindus.com.

ABOUT CORINDUS

Corindus, A Siemens Healthineers Company, is a global technology leader in robotic-assisted vascular interventions. The Company's CorPath® platform is a medical device to bring robotic precision to percutaneous coronary and vascular procedures. CorPath GRX is the second-generation robotic-assisted technology offering enhancements to the platform by adding important key upgrades that increase precision, improve workflow, and extend the capabilities and range of procedures that can be performed robotically. We are focused on developing innovative robotic solutions to revolutionize treatment of emergent conditions by providing specialized and timely medical care to patients around the world. For additional information, visit www.corindus.com, and follow @CorindusInc.

#

Remote capabilities are currently under development; it is not for sale. Its future availability cannot be guaranteed.

Media Contact:

Matter for Corindus

Jill Gross

978-518-4258

corindus@matternow.com

www.matternow.com